Investors

Investor Ready

2N Pharma is pioneering a new approach to treating neurodegenerative diseases by addressing dysfunctional metabolism in the brain. We have developed novel, small molecule, orally administered, therapeutic drug candidates that we believe will be transformational for the treatment of several brain diseases. Our lead drug candidate, Mitometin, is being optimized for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s Disease or MND, and we plan to commence clinical testing in 2022.

Please contact CEO and Co-Founder Preben Bruun-Nyzell at

Email: pbn@2npharma.com

Tel.: +46 760 58 01 08

investors

Investors


Creation House Program
2N Pharma is proud to have joined the BioInnovation Institute’s Creation House Program, joining a stable of  life science innovators, helping accelerate our research and bring treatments rapidly to market.

The Creation House program is supporting early-stage start-ups, who have achieved proof of concept and a business plan. This 18-months long program is designed to mature companies to a competitive international level and to build a case that is focusing on science, business and attracting funding. 

Read the BioInnovation Institute’s news article


Innobooster
Innovation Fund Denmark has awarded 2N Pharma an Innobooster grant of 80.000 USD that assists us in the preclinical development of a drug for Parkinson’s Disease. This grant enables us to expand the efficacy testing of our novel molecules in pre-clinical models of Parkinson’s Disease.  

Innovation Fund Denmark invests in the development of promising, innovative ideas into new solutions that create value and help to solve the challenges of our society.

Find out more about the Innobooster grant